What is NovoCure's net investment in lease?

NovoCure (NVCR) reported net investment in lease of $45.48M in Q1 2026.

How has NovoCure's net investment in lease changed year-over-year?

NovoCure's net investment in lease decreased by 6.3% year-over-year, from $48.51M to $45.48M.

What is the long-term trend for NovoCure's net investment in lease?

Over 5 years (2020 to 2025), NovoCure's net investment in lease has grown at a 20.0% compound annual growth rate (CAGR), from $19.01M to $47.33M.

NovoCure NVCR Net Investment in Lease

Net Investment in Lease at other companies

Boston ScientificBSX

——

Iovance Biotherapeutics, Inc.IOVA

——

Nuvation BioNUVB

——

Syndax PharmaceuticalsSNDX

——

ArriVent BioPharma, Inc.AVBP

——

Ethos Technologies, Inc. LIFE

——

Other financials

Income statement

See full

Revenue$174.1M+12.3%

Gross profit$135.1M+16.0%

Operating income-$67.4M-78.1%

Net income-$71.1M-107%

EPS (diluted)-$0.62-100%

Balance sheet

See full

Cash & equivalents$87.5M-31.2%

Total debt$39.5M-2.1%

Total equity$330.7M-8.6%

Total assets$787.9M-36.9%

Cash flow

See full

Operating cash flow-$13.5M+62.1%

CapEx$5.2M-51.4%

Free cash flow-$18.7M+59.7%

Valuation

See full

Market cap$1.7B-36.7%

Enterprise value$1.66B-36.3%

P/S2.5×-1.8×

Profitability

See full

Gross margin75.2%-2.0pp

Operating margin-27.2%+0.4pp

Net margin-25.7%-0.7pp

FCF margin-7.1%-2.0pp

Returns & leverage

See full

Return on equity-50%+5.4pp

Debt / equity0.1×0.0×

Current ratio2.9×+1.4×

Where this comes from

Reported directly by NovoCure in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: NovoCure’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about NovoCure's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is NovoCure's net investment in lease?: NovoCure (NVCR) reported net investment in lease of $45.48M in Q1 2026.
How has NovoCure's net investment in lease changed year-over-year?: NovoCure's net investment in lease decreased by 6.3% year-over-year, from $48.51M to $45.48M.
What is the long-term trend for NovoCure's net investment in lease?: Over 5 years (2020 to 2025), NovoCure's net investment in lease has grown at a 20.0% compound annual growth rate (CAGR), from $19.01M to $47.33M.